Edgewell Personal Care (EPC)
NYSE:EPC
Top Page
Edgewell Personal Care
(NYSE:EPC)
Select Model
Select Model
Rating:52Neutral
Price Target:
$23.00
▲(11.00% Upside)
Action:ReiteratedDate:02/09/26
The score is held back primarily by weakening financial performance (profitability and cash flow deterioration) and a high P/E valuation. Technicals are supportive but somewhat overextended, while the latest earnings update was constructive on guidance and strategic focus but still highlighted meaningful near-term margin and demand headwinds.
Positive Factors
Diversified, well-known brand portfolio
Edgewell's portfolio of enduring consumer brands across shaving, sun care, grooming and infant/feminine channels provides durable shelf presence, pricing power and customer loyalty. This category diversification reduces cyclicality and supports steady revenue base and long-term cash generation potential.
Negative Factors
Deteriorating cash generation and profitability
Material cooling of operating and free cash flow reduces the company's ability to fund capex, deleverage, repurchase shares or invest in marketing/innovation without external financing. Persistently lower cash conversion versus earnings constrains strategic flexibility for multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified, well-known brand portfolio
Edgewell's portfolio of enduring consumer brands across shaving, sun care, grooming and infant/feminine channels provides durable shelf presence, pricing power and customer loyalty. This category diversification reduces cyclicality and supports steady revenue base and long-term cash generation potential.
Read all positive factors
Edgewell Personal Care (EPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$967.97M
Dividend Yield3.51%
Average Volume (3M)800.44K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth-1.34%
EPS Growth-73.59%
CountryUS
Employees6,700
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.16
Shares Outstanding46,716,606
10 Day Avg. Volume775,628
30 Day Avg. Volume800,439
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.62
Price to Sales (P/S)0.43
P/FCF Ratio23.36
Enterprise Value/Market Cap2.37
Enterprise Value/Revenue1.06
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda15.27
Forecast
1Y Price Target
$24.33Price Target Upside17.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.92
Revenue Forecast (FY)$2.00B
Edgewell Personal Care Business Overview & Revenue Model
Company Description
Edgewell Personal Care Company, together with its subsidiaries, manufactures and markets personal care products worldwide. It operates through three segments: Wet shave, Sun and Skin care, and Feminine care. The Wet Shave segment provides razor sy...
How the Company Makes Money
Edgewell Personal Care generates revenue primarily through the sale of its branded consumer products across multiple categories. The company's key revenue streams include sales from its shaving products, which are a significant portion of its offe...
Edgewell Personal Care Key Performance Indicators (KPIs)
Edgewell Personal Care Earnings Call Summary
Earnings Call Date:Feb 09, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but constructive picture: notable strategic progress (feminine care divestiture completed, proceeds used to reduce debt, strong Sun Care and Grooming growth, 240 bps productivity gains, and international share gains) alongside meaningful near-term challenges (continuing-operations top-line softness, Wet Shave and Skincare declines, Q1 gross margin pressure from inflation/tariffs, GAAP losses, and divestiture-related stranded costs). Management kept FY26 guidance intact for continuing operations, signaled H2 improvement driven by distribution, innovation and pricing, and emphasized a multi-quarter path to margin and cash-flow recovery.Positive Updates
Feminine Care Divestiture Closed
Sale of the feminine care business to Essity closed on Feb 2, 2026; expected annualized benefit to margins and strategy focus; pro forma impact to continuing operations estimated at a $0.44 headwind to adjusted EPS and $44M to adjusted EBITDA in FY2026 (note: normalized 12-month impact would be ~ $0.20 adj EPS / $36M adj EBITDA, better than prior outlook).
Negative Updates
Continuing Operations Top-Line Pressure
Continuing operations organic net sales decreased 50 basis points in Q1; Q2 organic sales expected to be down ~3% and first half net sales ~down 2% due to timing/phasing and NPD timing in Japan.
Read all updates
Q1-2026 Updates
Positive
Negative
Feminine Care Divestiture Closed
Sale of the feminine care business to Essity closed on Feb 2, 2026; expected annualized benefit to margins and strategy focus; pro forma impact to continuing operations estimated at a $0.44 headwind to adjusted EPS and $44M to adjusted EBITDA in FY2026 (note: normalized 12-month impact would be ~ $0.20 adj EPS / $36M adj EBITDA, better than prior outlook).
Read all positive updates
Company Guidance
Edgewell reiterated its fiscal 2026 continuing‑operations guidance: organic net sales -1% to +2% (ex‑~150 bps currency), with Q2 organic sales ~‑3% and H1 net sales ~‑2%; management expects mid‑single‑digit international growth (resuming in Q2) and to generate ~two‑thirds of adjusted EBITDA in H2. They forecast ~60 bps of full‑year gross‑margin rate accretion (Q2 margin guided to 43–44%) as Q1 productivity of ~240 bps helps offset ~450 bps of core inflation/volume pressure and a net ~$25M tariff headwind; A&P is expected to rise ~70 bps to ~12.3% of sales, driving an adjusted operating‑margin decline of ~50 bps. Full‑year targets include adjusted EBITDA of $245–$265M and adjusted EPS of $1.70–$2.10 (incorporating a $0.44 EPS and $44M EBITDA headwind from the feminine‑care divestiture; normalized annualized divestiture impact ~ $0.20 EPS / $36M EBITDA), adjusted free cash flow (ex‑divestiture) of $80–$110M, and roughly 85% of adjusted EPS realized in H2; capex is near its peak and proceeds from the divestiture will be used primarily to reduce debt.Edgewell Personal Care Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
58
Neutral
Cash Flow
46
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.17B | 2.22B | 2.25B | 2.25B | 2.17B | 2.09B |
| Gross Profit | 894.30M | 924.90M | 955.70M | 940.80M | 880.50M | 951.20M |
| EBITDA | 150.50M | 185.60M | 285.40M | 317.60M | 285.40M | 302.10M |
| Net Income | -38.20M | 25.40M | 98.60M | 114.70M | 99.50M | 117.80M |
Balance Sheet | ||||||
| Total Assets | 3.77B | 3.76B | 3.73B | 3.74B | 3.71B | 3.67B |
| Cash, Cash Equivalents and Short-Term Investments | 223.30M | 225.70M | 209.10M | 216.40M | 188.70M | 479.20M |
| Total Debt | 1.55B | 1.54B | 1.39B | 1.45B | 1.46B | 1.32B |
| Total Liabilities | 2.28B | 2.20B | 2.15B | 2.20B | 2.25B | 2.09B |
| Stockholders Equity | 1.49B | 1.55B | 1.58B | 1.54B | 1.47B | 1.58B |
Cash Flow | ||||||
| Free Cash Flow | 36.30M | 41.40M | 174.50M | 166.60M | 45.60M | 172.20M |
| Operating Cash Flow | 108.10M | 118.40M | 231.00M | 216.10M | 102.00M | 229.00M |
| Investing Cash Flow | -67.10M | -72.90M | -62.40M | -50.50M | -355.40M | -48.70M |
| Financing Cash Flow | -6.50M | -30.00M | -179.40M | -146.50M | -17.60M | -65.40M |
Edgewell Personal Care Technical Analysis
Positive
20.72
Price Trends
20.68
Positive
19.11
Positive
20.54
Positive
Market Momentum
0.14
Negative
50.51
Neutral
67.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EPC, the sentiment is Positive. The current price of 20.72 is above the 20-day moving average (MA) of 20.35, above the 50-day MA of 20.68, and above the 200-day MA of 20.54, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 50.51 is Neutral, neither overbought nor oversold. The STOCH value of 67.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EPC.
Edgewell Personal Care Risk Analysis
Edgewell Personal Care disclosed 28 risk factors in its most recent earnings report. Edgewell Personal Care reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Edgewell Personal Care Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $21.91B | 27.62 | 17.16% | 1.38% | 1.45% | 42.04% | |
68 Neutral | $1.76B | 12.42 | 5.52% | 3.15% | -5.21% | 1.96% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $30.89B | 16.63 | 155.28% | 5.03% | -10.04% | -23.41% | |
52 Neutral | $967.97M | -3.02 | -2.50% | 3.51% | -1.34% | -73.59% | |
50 Neutral | $1.86B | -5.46 | -14.49% | ― | -5.68% | -358.36% | |
49 Neutral | $1.49B | -5.46 | -10.89% | 7.76% | -5.88% | 90.23% |
* Consumer Defensive Sector Average
EPC
Edgewell Personal Care
20.72
-5.97
-22.37%
CHD
Church & Dwight
92.55
-7.75
-7.72%
KMB
Kimberly Clark
93.05
-34.55
-27.08%
NWL
Newell Brands
3.56
-0.66
-15.62%
SPB
Spectrum Brands Holdings
76.06
18.94
33.15%
COTY
Coty
2.11
-2.58
-55.01%
Edgewell Personal Care Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsShareholder Meetings
Edgewell Reaffirms Outlook After Feminine Care Divestiture
Positive
Feb 9, 2026
At its February 5, 2026 annual meeting, Edgewell shareholders approved the company’s 3rd Amended and Restated 2018 Stock Incentive Plan, adding 2.1 million authorized shares, removing the fungible share ratio for new awards, and updating pro...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Edgewell Completes Feminine Care Divestiture to Essity
Positive
Feb 6, 2026
On February 2, 2026, Edgewell Personal Care completed the previously announced sale of its Feminine Care business to Swedish health and hygiene group Essity for approximately $340 million in cash, transferring specified assets and liabilities unde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.